Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 418

Sort by

Sort Order Select

Journal Articles

The AHR: adaptive evolution or one-off?

Michael H. Kroll

Blood (2019) 134 (26): 2337–2338.

https://doi.org/10.1182/blood.2019003943

Published: 2019

Journal Articles

Metabolites in a mouse cancer model enhance venous thrombogenicity through the aryl hydrocarbon receptor–tissue factor axis

Mostafa Belghasem, Daniel Roth, Sean Richards, Marc Arthur Napolene, Joshua Walker, Wenqing Yin, Nkiruka Arinze, Chimera Lyle, Cheryl Spencer, Jean M. Francis, Cristal Thompson, Christopher Andry, Stephen A. Whelan, Norman Lee, Katya Ravid, Vipul C. Chitalia

Blood (2019) 134 (26): 2399–2413.

https://doi.org/10.1182/blood.2019001675

Published: 2019

Includes: Supplemental data

Journal Articles

Lgr5 Functions As a Critical Negative Regulator of Wnt/β-Catenin Signaling and Is Essential for B-Lymphopoiesis and Malignant B-Cell Transformation

Kadriye Nehir Cosgun, PhD, Gauri Deb, MS, PhD, Xin Yang, MD, Gang Xiao, PhD, Teresa Sadras, PhD, Jaewoong Lee, PhD, Lai N Chan, PhD, Kohei Kume, PhD, Lu Yang, PhD, Huimin Geng, PhD, John Chan, MD, Joo Y. Song, MD, Hassan Jumaa, PhD, Andrew G. Polson, PhD, Hans Clevers, MD PhD, Markus Müschen, MD PhD

Blood (2019) 134 (Supplement_1): 748.

https://doi.org/10.1182/blood-2019-127263

Published: 2019

Journal Articles

Clinical Outcomes and Characteristics of Patients (pts) with FLT3 -Internal Tandem Duplication ( FLT3 -ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Undergoing Hematopoietic Stem Cell Transplant (HSCT) after Quizartinib (Q) or Salvage Chemotherapy (SC) in the Quantum-R Trial

Siddhartha Ganguly, MD, Jorge E. Cortes, MD, Alwin Krämer, MD, Mark J. Levis, MD, Giovanni Martinelli, MD, Alexander E. Perl, MD, Nigel H. Russell, MD, Meena Arunachalam, PharmD, Guy Gammon, MBBS, MRCP, Arnaud Lesegretain, Derek E. Mires, PharmD, Ruth Namuyinga, MD MPH, Yufen Zhang, PhD, Samer K. Khaled, MD

Blood (2019) 134 (Supplement_1): 736.

https://doi.org/10.1182/blood-2019-124504

Published: 2019

Journal Articles

Effect of Co-Mutations and FLT3 -ITD Variant Allele Frequency (VAF) on Response to Quizartinib or Salvage Chemotherapy (SC) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Blood (2019) 134 (Supplement_1): 737.

https://doi.org/10.1182/blood-2019-121880

Published: 2019

Journal Articles

Phase II Randomized Trial of Gilteritinib Vs Midostaurin in Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML)

Selina M. Luger, MD FRCPC, Zhuoxin Sun, PhD, Sanam Loghavi, MD, Hillard M Lazarus, MD, Jacob M. Rowe, MB, BS, Martin S. Tallman, MD, Keith W. Pratz, MD, Mark Litzow, MD

Blood (2019) 134 (Supplement_1): 1309.

https://doi.org/10.1182/blood-2019-128377

Published: 2019

Journal Articles

Iron-Chelating Potential of Novel Phytochemicals in Poplar and Cedar Trees

Sarah Lane, BSc, Juergen Ehlting, MSc, PhD, Patrick B Walter, MSc, PhD

Blood (2019) 134 (Supplement_1): 4806.

https://doi.org/10.1182/blood-2019-127259

Published: 2019

Journal Articles

Effectiveness of Prophylaxis with Granulocyte Colony-Stimulating Factor Among Cancer Patients Receiving Myelosuppressive Chemotherapy in US Clinical Practice

Kathryn Richert-Boe, MD MPH, Lois Lamerato, PhD, Gary H. Lyman, MD MPH, Manpreet Kaur, MPH, MBA, Neel Shah, BPharm, PhD, Tatiana Lawrence, MD, Devi Sundaresan, MS, Amanda Silvia, BS, Ahuva Hanau, BS, Derek Weycker, PhD

Blood (2019) 134 (Supplement_1): 4688.

https://doi.org/10.1182/blood-2019-123559

Published: 2019

Journal Articles

Second Primary Malignancy Among Patients with Plasma Cell Myeloma Receiving First-Line Lenalidomide-Based Therapy: A Population-Based Analysis

Smith Giri, MBBS, Peter Barth, MD, Luciano J. Costa, MD PhD, Adam J Olszewski, MD

Blood (2019) 134 (Supplement_1): 1862.

https://doi.org/10.1182/blood-2019-131231

Published: 2019

Journal Articles

Emerging Mutations at Relapse in Patients with FLT3 -Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial

Catherine C. Smith, MD, Mark J. Levis, MD, Alexander E. Perl, MD, Giovanni Martinelli, MD, Andreas Neubauer, MD, Ellin Berman, MD, Pau Montesinos, MD PhD, Maria R. Baer, MD, Richard A. Larson, MD, Wen-Chien Chou, MD, PhD, Hisayuki Yokoyama, MD PhD, Christian Recher, MD PhD, Sung-Soo Yoon, MD PhD, Jason E. Hill, Matt Rosales, Erkut Bahceci

Blood (2019) 134 (Supplement_1): 14.

https://doi.org/10.1182/blood-2019-122620

Published: 2019

Journal Articles

Identifying miRNA Biomarkers and Predicted Targets Associated with Venous Thromboembolism in Colorectal Cancer Patients

Ann S. Kim, BA, Matthew F Kalady, MD, Jennifer DeVecchio, Kahraman Tanriverdi, Jane E. Freedman, MD, John Barnard, PhD, Tae Hyun Hwang, PhD, Alok A Khorana, MD, Keith R McCrae, MD

Blood (2019) 134 (Supplement_1): 3643.

https://doi.org/10.1182/blood-2019-127585

Published: 2019

Journal Articles

A Systematic Review and Meta- Analysis of Randomized Controlled Trials on Primary Ambulatory Thromboprophylaxis (PATP) in Patients with Gastrointestinal Cancers Receiving Chemotherapy

Kyaw Zin Thein, MDMBBS, Donald P. Quick, MD, Thein Hlaing Oo, MD

Blood (2019) 134 (Supplement_1): 3679.

https://doi.org/10.1182/blood-2019-126732

Published: 2019

Journal Articles

Concurrent Treatment of VEGFR Tyrosine Kinase Inhibitors (TKIs) and Factor Xa Inhibitors Is Associated with Increased Bleeding Risks

Sandip Patel, MBBS, Tiffany George, MD, Tzu-Fei Wang, MD MPH, Sherry Mori Vogt, Pharm D, Edmund Folefac, MD, Ming Yin, MD

Blood (2019) 134 (Supplement_1): 3681.

https://doi.org/10.1182/blood-2019-130465

Published: 2019

Journal Articles

Use of Anticoagulants of Patients with Cancer-Associated Thrombosis Beyond 6 Months ; The Uscat Study, a 432-Patient Retrospective Non-Interventional Study

Isabelle Mahe, MD PhD, Ludovic Plaisance, MD, Céline Chapelle, Silvy Laporte, MS, PhD, Benjamin Planquette, MD PhD, Laurent Bertoletti, MD PhD, Jean Chidiac, MD, Francis Couturaud, MD PhD, Lionel Falchiero, MD, Nicolas Falvo, MD, Isild Mahé, Hélène Helfer, PhD, Guy Meyer

Blood (2019) 134 (Supplement_1): 3664.

https://doi.org/10.1182/blood-2019-124745

Published: 2019

Journal Articles

A 20-Year Review of Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients after Failure with Interferon Therapy

Maria R Vazquez, Hagop M. Kantarjian, MD, Gautam M. Borthakur, MD, Susan O'Brien, MD, Srdan Verstovsek, MD PhD, Farhad Ravandi, MD, Alessandra Ferrajoli, MD, Jorge E. Cortes, MD, Tapan M. Kadia, MD, William G. Wierda, MD PhD, Guillermo Garcia-Manero, MD, Sara E Dellasala, BS, Kathleen A Kehr, MD, Sherry A. Pierce, BSN, BA, Mary B. Rios, RN, Elias Jabbour, MD

Blood (2019) 134 (Supplement_1): 2927.

https://doi.org/10.1182/blood-2019-132246

Published: 2019

Journal Articles

Tudor Domain-Focused CRISPR Dropout Screen Identifies SGF29 As a Novel Essential Gene in MLL -Rearranged Leukemias

Anthony K. N. Chan, PhD, Christopher D. Delaney, Lu Yang, PhD, Wen-Han Chang, PhD, Kazuya Miyashita, PhD, Qiao Liu, MD, Sheela Pangeni Pokharel, MSc, Scott A. Armstrong, MD PhD, Chun-Wei David Chen, PhD

Blood (2019) 134 (Supplement_1): 530.

https://doi.org/10.1182/blood-2019-131467

Published: 2019

Journal Articles

Randomized Trial of Lenalidomide and Dexamethasone Versus Clarythromycin, Lenalidomide and Dexamethasone As First Line Treatment in Patients with Multiple Myeloma Not Candidates for Autologous Stem Cell Transplantation: Results of the GEM-Claridex Clinical Trial

Noemi Puig, MD PhD, Miguel T Hernández, Laura Rosinol Dachs, Esther González Garcia, MD, Felipe De Arriba, PhD, Albert Oriol, MD, Veronica Gonzalez-Calle, Fernando Escalante, MD, Javier De La Rubia, Mercedes Gironella Meda, Rafael Ríos Tamayo, Ricarda Belen Garcia Sanchez, José María Arguiñano Pérez, MD, Adrián Alegre Amor, MD, Jesús Martín, Norma C. Gutierrez, MD PhD, Maria Jose Calasanz, PhD BSc, Maria Luisa Martin-Ramos, María del Carmen Couto Caro, Maria Casanova, MD, Mario Arnao, MD, Ernesto Pérez Persona, Sebastián Garzón López, Marta Sonia Gonzalez, MD, Guillermo Martín Sánchez, MD, Adriana C. Rossi, MD MSc, Morton Coleman, MD, Cristina Encinas, Ana María Vale López, Ana Isabel Teruel, MDcal Doctor, Bruno Paiva, PhD, Maria Teresa Cedena Romero, MD PhD, Jesús San-Miguel, Juan Jose Lahuerta, MD PhD, Joan Bladé, MD, Ruben Niesvizky, MD, Maria-Victoria Mateos

Blood (2019) 134 (Supplement_1): 694.

https://doi.org/10.1182/blood-2019-123997

Published: 2019

Journal Articles

Extended Mutational Profiling By MSK-IMPACT TM Identifies Mutations Predicting Thromboembolic Risk in Patients with Solid Tumor Malignancy

Andrew Dunbar, MD, Kelly Bolton, MD PhD, Sean M. Devlin, PhD, Francisco Sanchez-Vega, PhD, Jianjiong Gao, PhD, Jodi V. Mones, MD, Jonathan M. Wills, BA, Daniel Kelly, MS, Mirko Farina, MD, Sirish Kishore, MD, Krishna Juluru, MD, Neil Iyengar, MD, David M. Hyman, MD, Ahmet Zehir, PhD, Wungki Park, MD, Alok A Khorana, MD, Gerald A. Soff, MD, Simon Mantha, MDMPH

Blood (2019) 134 (Supplement_1): 633.

https://doi.org/10.1182/blood-2019-124242

Published: 2019

Journal Articles

Cells Deficient in the Shwachman-Diamond Syndrome Protein SBDS or the Diamond-Blackfan Anemia Protein RPS19 Have Impaired Homologous Recombination

Elif Asik, PhD, Nimrat Chatterjee, PhD, Alison A. Bertuch, MD PhD

Blood (2019) 134 (Supplement_1): 104.

https://doi.org/10.1182/blood-2019-128953

Published: 2019

Journal Articles

A Phase 1/2 Study of Quizartinib (Q) in Combination with Re-Induction Chemotherapy and As Single-Agent Continuation Therapy in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) FLT3 -ITD Acute Myeloid Leukemia (AML)

C. Michel Zwaan, MD PhD, Edward Anders Kolb, MD, Derek E. Mires, PharmD, Michele Vigliotti, PharmD, Jingdong Xie, PhD, Pamela Downs, BS, Arthur P DeCillis, MD MS, Cara A Rabik, MD PhD, Todd M Cooper, DO

Blood (2019) 134 (Supplement_1): 3937.

https://doi.org/10.1182/blood-2019-121736

Published: 2019

NARROW

The AHR: adaptive evolution or one-off?

Metabolites in a mouse cancer model enhance venous thrombogenicity through the aryl hydrocarbon receptor–tissue factor axis

Lgr5 Functions As a Critical Negative Regulator of Wnt/β-Catenin Signaling and Is Essential for B-Lymphopoiesis and Malignant B-Cell Transformation

Clinical Outcomes and Characteristics of Patients (pts) with FLT3 -Internal Tandem Duplication ( FLT3 -ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Undergoing Hematopoietic Stem Cell Transplant (HSCT) after Quizartinib (Q) or Salvage Chemotherapy (SC) in the Quantum-R Trial

Effect of Co-Mutations and FLT3 -ITD Variant Allele Frequency (VAF) on Response to Quizartinib or Salvage Chemotherapy (SC) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Phase II Randomized Trial of Gilteritinib Vs Midostaurin in Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML)

Iron-Chelating Potential of Novel Phytochemicals in Poplar and Cedar Trees

Effectiveness of Prophylaxis with Granulocyte Colony-Stimulating Factor Among Cancer Patients Receiving Myelosuppressive Chemotherapy in US Clinical Practice

Second Primary Malignancy Among Patients with Plasma Cell Myeloma Receiving First-Line Lenalidomide-Based Therapy: A Population-Based Analysis

Emerging Mutations at Relapse in Patients with FLT3 -Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial

Identifying miRNA Biomarkers and Predicted Targets Associated with Venous Thromboembolism in Colorectal Cancer Patients

A Systematic Review and Meta- Analysis of Randomized Controlled Trials on Primary Ambulatory Thromboprophylaxis (PATP) in Patients with Gastrointestinal Cancers Receiving Chemotherapy

Concurrent Treatment of VEGFR Tyrosine Kinase Inhibitors (TKIs) and Factor Xa Inhibitors Is Associated with Increased Bleeding Risks

Use of Anticoagulants of Patients with Cancer-Associated Thrombosis Beyond 6 Months ; The Uscat Study, a 432-Patient Retrospective Non-Interventional Study

A 20-Year Review of Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients after Failure with Interferon Therapy

Tudor Domain-Focused CRISPR Dropout Screen Identifies SGF29 As a Novel Essential Gene in MLL -Rearranged Leukemias

Randomized Trial of Lenalidomide and Dexamethasone Versus Clarythromycin, Lenalidomide and Dexamethasone As First Line Treatment in Patients with Multiple Myeloma Not Candidates for Autologous Stem Cell Transplantation: Results of the GEM-Claridex Clinical Trial

Extended Mutational Profiling By MSK-IMPACT TM Identifies Mutations Predicting Thromboembolic Risk in Patients with Solid Tumor Malignancy

Cells Deficient in the Shwachman-Diamond Syndrome Protein SBDS or the Diamond-Blackfan Anemia Protein RPS19 Have Impaired Homologous Recombination

A Phase 1/2 Study of Quizartinib (Q) in Combination with Re-Induction Chemotherapy and As Single-Agent Continuation Therapy in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) FLT3 -ITD Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only